Pacira BioSciences Inc. (PCRX) exhibits 79.4% gross margins and 1.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 51.6x enterprise multiple and 4.8% implied options volatility.
Sustained 79.4% gross profitability converts into 2.6% operating margin and 1.7% ROIC, outpacing sector cost of capital.
ROIC: 1.7% // GM: 79.4%YoY revenue trajectory of +3.6% paired with 9.42% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +3.6% // FCF YLD: 9.42%Altman Z-Score of 2.33 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.33 // F-SCORE: 8/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 51.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $36.39 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 1.0% net margins.
NET MARGIN: 1.0% // D/E: 0.54x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PCRX & activate live FRED threshold breach alerts.